Lundbeck is a niche player exclusively focused on the treatment of CNS and mental health disorders. How developed do you find this niche to be in…
In Conversation
Focus Reports first met with Materia Medica in 2006. At the time, the company was enjoying an extremely rapid pace of growth. Looking back over the…
As the 7th largest pharma MNC worldwide, AstraZeneca is a company that needs no introduction. However, our readers would love to hear more about your operations…
Two weeks ago, Lupin announced its annual results, portraying 6 years of sustained growth and a net profit up by 27%. How pleased were you with…
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor…
When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that…
How does Janssen view the Serbian market today, and how has company built up its presence here in the country? Previously we were working through distribution…
Compared to 5 years ago, MNCs have increased their presence in India. Some even have become market leaders, particularly through acquisitions of domestic players. How is…
Novo Nordisk has a long history in Serbia compared to many of the other multinational companies present in the country today. The separate entity Novo Nordisk…
The AEB works through a number of channels to promote the interests of European corporations with operations in Russia. It has a long history in this…
If we first take a step back and look at how Bharat Biotech was established, we see quite a remarkable story. It is rather exceptional to…
Novo Nordisk announced last year the development of an insulin plant in the Kaluga region not far from Moscow. What is the strategic significance of this…
